What is the best NOAC drug for long term use in a 69 yr old male in sinus Rythm with previous documented Atrial Fibrillation and two successful Cardioversion

The short version: apixaban has the best safety profile for long-term use in a 69-year-old man with prior atrial fibrillation and successful cardioversion.

The evidence consistently shows apixaban has the lowest risk of major bleeding and intracranial hemorrhage among the NOACs, while providing stroke prevention at least as good as warfarin. The ARISTOTLE trial, a double-blind randomized study of 18,201 patients, found apixaban reduced stroke or systemic embolism to 1.27% per year versus 1.60% with warfarin, and major bleeding to 2.13% per year versus 3.09% [6, 9]. Intracranial hemorrhage was cut by more than half [6]. A 2018 real-world study of over 45,000 patients found apixaban had the lowest major bleeding risk of any NOAC, with a hazard ratio of 0.53 compared to warfarin [14]. The same study found rivaroxaban had a 1.82 times higher bleeding risk than apixaban [14].

Dabigatran 150 mg is slightly more effective than apixaban for preventing ischemic stroke, but it increases gastrointestinal bleeding. The RE-LY trial found dabigatran 150 mg reduced stroke to 1.11% per year versus 1.69% with warfarin, but gastrointestinal bleeding rose to 1.51% per year versus 1.02% [26]. A 2016 Medicare study of over 100,000 elderly patients found rivaroxaban had higher rates of intracranial hemorrhage, major extracranial bleeding, and gastrointestinal bleeding compared to dabigatran [13]. A 2018 primary care cohort study found rivaroxaban was associated with a 19% increase in all-cause mortality compared to warfarin [22].

For a 69-year-old man in sinus rhythm after successful cardioversion, the key question is long-term safety. The risk of recurrent atrial fibrillation is real, but the daily bleeding risk from anticoagulation is constant. Apixaban offers the best balance: effective stroke prevention with the lowest bleeding rates. The standard dose is 5 mg twice daily, reduced to 2.5 mg twice daily if he is over 80, weighs under 60 kg, or has a creatinine over 1.5 mg/dL [9].

My call: apixaban 5 mg twice daily is the best choice for long-term use in this patient, with the caveat that no NOAC has been compared to a true placebo in a modern long-term safety trial in sinus-rhythm patients after cardioversion. Confidence: moderate.